Activity of bacteriophages in removing biofilms of pseudomonas aeruginosa isolates from chronic rhinosinusitis patients by Fong, S. et al.
ORIGINAL RESEARCH
published: 22 September 2017
doi: 10.3389/fcimb.2017.00418
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 1 September 2017 | Volume 7 | Article 418
Edited by:
Dongsheng Zhou,




Institute for Bioengineering of
Catalonia, Spain
Wei Zhang,
Nanjing Agricultural University, China
Feng Han,




Received: 06 July 2017
Accepted: 08 September 2017
Published: 22 September 2017
Citation:
Fong SA, Drilling A, Morales S,
Cornet ME, Woodworth BA,
Fokkens WJ, Psaltis AJ, Vreugde S
and Wormald P-J (2017) Activity of
Bacteriophages in Removing Biofilms
of Pseudomonas aeruginosa Isolates
from Chronic Rhinosinusitis Patients.
Front. Cell. Infect. Microbiol. 7:418.
doi: 10.3389/fcimb.2017.00418
Activity of Bacteriophages in
Removing Biofilms of Pseudomonas
aeruginosa Isolates from Chronic
Rhinosinusitis Patients
Stephanie A. Fong 1, Amanda Drilling 1, Sandra Morales 2, Marjolein E. Cornet 3,
Bradford A. Woodworth 4, Wytske J. Fokkens 3, Alkis J. Psaltis 1, Sarah Vreugde 1 and
Peter-John Wormald 1*
1Department of Surgery—Otolaryngology, Head and Neck Surgery, The Queen Elizabeth Hospital, Woodville South, SA,
Australia, 2 AmpliPhi Australia, Brookvale, NSW, Australia, 3Department of Otorhinolaryngology, Academic Medical Center,
University of Amsterdam, Amsterdam, Netherlands, 4Department of Otolaryngology-Head and Neck Surgery, University of
Alabama at Birmingham, Birmingham, AL, United States
Introduction: Pseudomonas aeruginosa infections are prevalent amongst chronic
rhinosinusitis (CRS) sufferers. Many P. aeruginosa strains form biofilms, leading to
treatment failure. Lytic bacteriophages (phages) are viruses that infect, replicate within,
and lyse bacteria, causing bacterial death.
Aim: To assess the activity of a phage cocktail in eradicating biofilms of ex vivo
P.aeruginosa isolates from CRS patients.
Methods : P. aeruginosa isolates from CRS patients with and without cystic fibrosis
(CF) across three continents were multi-locus sequence typed and tested for antibiotic
resistance. Biofilms grown in vitro were treated with a cocktail of four phages (CT-PA).
Biofilm biomass was measured after 24 and 48 h, using a crystal violet assay. Phage
titrations were performed to confirm replication of the phages. A linear mixed effects
model was applied to assess the effects of treatment, time, CF status, and multidrug
resistance on the biomass of the biofilm.
Results: The isolates included 44 strain types. CT-PA treatment significantly reduced
biofilm biomass at both 24 and 48 h post-treatment (p< 0.0001), regardless of CF status
or antibiotic resistance. Biomass was decreased by a median of 76% at 48 h. Decrease
in biofilm was accompanied by a rise in phage titres for all except one strain.
Conclusion: A single dose of phages is able to significantly reduce biofilms formed in
vitro by a range of P.aeruginosa isolates from CRS patients. This represents an exciting
potential and novel targeted treatment for P. aeruginosa biofilm infections and multidrug
resistant bacteria.
Keywords: bacteriophage, Pseudomonas aeruginosa, chronic rhinosinusitis, cystic fibrosis, biofilm, multidrug
resistant
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INTRODUCTION
Chronic rhinosinusitis (CRS) is an inflammatory condition of
the nose and paranasal sinuses, persisting for 12 weeks or
longer. Bacterial biofilms have been implicated in recalcitrant
CRS and increase the tolerance of bacteria to antibiotics through
numerous mechanisms. These include metabolic heterogeneity
of the bacteria within the biofilm, enzymatic deactivation, anionic
charges due to extracellular DNA within the biofilm matrix, and
changes in gene expression (de la Fuente-Nú-ez et al., 2013).
Biofilms have been found on the sinonasal mucosa of up to
54% of CRS sufferers, compared to 8% of control patients (Chen
et al., 2012). Furthermore, multiple studies have noted a higher
prevalence of biofilms in patients who are undergoing revision
surgery (Psaltis et al., 2007; Chen et al., 2012). In particular,
the presence of biofilm-forming Pseudomonas aeruginosa strains
has been associated with poor resolution of symptoms and signs
of CRS following endoscopic sinus surgery (Bendouah et al.,
2006).
P. aeruginosa has been identified in the sinuses of 9% of CRS
patients, and is associated with poorer quality of life measured
by disease severity scores, such as the Visual Analogue Scale
(VAS) and Sinonasal Outcome Test-22 (SNOT-22) (Cleland
et al., 2013, 2016). P. aeruginosa sinus infections also commonly
aﬄict patients with cystic fibrosis (CF), with the species being
identified in sinus cultures of up to 49% of CF patients with CRS
(Rasmussen et al., 2012). Moreover, P. aeruginosa is intrinsically
resistant to many classes of antibiotics, and acquired antibiotic
resistance is increasing worldwide. New therapeutic strategies
are therefore required to combat these difficult to treat bacterial
infections in the context of CRS.
Bacteriophages are viruses that infect bacteria. Lytic
bacteriophages are able to lyse their host bacterium, after
replicating themselves within the host bacterium. Lysis of the
host not only kills the bacterium, but also releases the progeny
copies of the phage for re-infection of other bacteria (Guttman
et al., 2004). Bacteriophages are species specific, and so can
be used to target pathogenic bacteria, without disturbing non-
harmful commensal bacteria (Hanlon, 2007). Bacteriophages
are also able to penetrate bacterial biofilms (Vilas Boas et al.,
2016).
These characteristics make bacteriophages an attractive non-
antibiotic therapy for treating bacterial biofilms in CRS. This
study aims to assess the activity of a cocktail (mixture) of
four P. aeruginosa bacteriophages (CT-PA) in removing ex vivo
biofilms formed by PA isolates from CRS patients, both with
and without CF. The prevalence of antibiotic resistance in these
clinical isolates was also assessed.
METHODS
Bacterial Strains and Growth Conditions
This study was approved by the Human Research Ethics
Committee of The Queen Elizabeth Hospital, Adelaide, South
Australia.
P. aeruginosa strains were isolated by an independent
pathology laboratory (Adelaide Pathology Partners, Adelaide,
South Australia) from endoscopically-guided sinus swabs, from
patients who met the European Position Paper on Rhinosinusitis
and Nasal Polyps (EPOS) 2012 criteria for chronic rhinosinusitis
(Fokkens et al., 2012). Clinical P. aeruginosa isolates of
patients with CF were kindly donated by the Department of
Otorhinolaryngology, Academic Medical Centre (Amsterdam,
Netherlands) and P. aeruginosa sinus isolates from CRS patients
with and without CF were kindly donated by the Department
of Otolaryngology-Head and Neck Surgery, University of
Alabama at Birmingham (Birmingham, AL). P. aeruginosa
isolates were stored in 25% glycerol in nutrient broth at
−80◦C. P. aeruginosa laboratory reference strain ATCC 15692
(PAO1) was obtained from American Type Culture Collection
(Manassas, VA, USA) as a control for phage sensitivity and
biofilm assays. Isolates were plated from frozen glycerol stocks
onto 1.5% nutrient agar, and broth cultures were grown in
nutrient broth. Agar plates and broth cultures were incubated
at 37◦C.
Bacteriophage Cocktail
Stocks of 4 anti-P. aeruginosa bacteriophages (Pa 193, Pa
204, Pa 222, Pa 223), as well as heat-inactivated stocks, were
supplied by AmpliPhi Biosciences (Brookvale, New SouthWales,
Australia). Pa 193 and Pa 204 are of the Myoviridae family,
and Pa 222 and Pa 223 are of the Podoviridae family. All
4 phages have been characterized as strictly lytic by genome
sequencing (unpublished data). Prior to each assay, the stock
suspension of each bacteriophage was titrated against a selected
P. aeruginosa bacterial strain using the soft agar overlay small
drop assay, as described below. Equal concentrations of each
bacteriophage were combined to form the bacteriophage cocktail
(CT-PA).
Multi-Locus Sequence Typing
The protocol for multi-locus sequence typing (MLST) of
P. aeruginosa isolates has been described by Curran et al (Curran
et al., 2004). For each strain, a single colony was used to inoculate
5 mL of nutrient broth, and the culture was grown overnight
on a shaker at 37◦C. DNA extraction from a 1 mL aliquot of
the overnight culture was performed using the DNeasy Blood
and Tissue DNA extraction kit (Qiagen, Hilden, Germany),
following the protocol for Gram negative bacteria recommended
by the manufacturer. PCR of the 7 MLST loci was performed
using the Taq PCR kit (New England Biolabs, Ipswich MA,
USA) using the protocol and primers described by Curran
et al (GeneWorks, Adelaide, South Australia). PCR products
TABLE 1 | Characteristics of P. aeruginosa clinical isolates studied.
CF isolates Non-CF isolates Total
Country of origin Australia 2 19 21
Netherlands 19 0 19
USA 3 4 7
Total 24 23 47
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were purified using the QIAquick PCR Purification kit (Qiagen,
Hilden, Germany), following the manufacturer’s protocol. Sanger
sequencing was performed on the purified PCR products by
two external laboratories (SA Pathology and Australian Genome
Research Facility, Adelaide, South Australia). Sequences were
checked for base miscalls, and contigs were assembled using
GeneStudio Professional, version 2.2.0.0 (GeneStudio Inc.). The
sequence of each locus was matched to the allele sequences in the
P. aeruginosa MLST database (pubmlst.org/paeruginosa/) and
assigned the corresponding allele number. The profile of alleles
for each isolate was then matched to the sequence type profiles in
the MLST database.
FIGURE 1 | Condensed phylogenetic tree obtained using the Neighbor-Joining method. Phylogeny was inferred using the Neighbor-Joining method. The condensed
topology after branches with bootstrap values of <50% have been collapsed into polytomies is shown. The percentages of replicate trees in which the associated
taxa clustered together in the bootstrap test (2,000 replicates) are shown next to the branches. There were a total of 2,882 positions in the final dataset. Multidrug
resistant isolates are labeled in red, and CT-PA phage cocktail resistant isolates are labeled in teal.
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Phylogenetic and Burst Analysis
Phylogenetic analysis of the clinical isolates and laboratory
reference strain PAO1 were conducted using MEGA version
6.06 (Tamura et al., 2013). MLST sequence alleles for each
of the 7 loci were aligned using the MUSCLE programme in
MEGA (Edgar, 2004). The concatenated alignments were used
to generate dendrograms using the Neighbor-Joining method
FIGURE 2 | Spot test assay. Phage activity on the spot test assay was graded
as: (A) Full activity—a completely clear (non-turbid) spot with no bacterial
growth observed within the spot, (B) Partial activity—a turbid spot easily seen
with the naked eye, or a clear spot containing isolated bacterial colonies, or
(C) No activity—no easily discernible spot seen with the naked eye.
with bootstrapping analysis (2,000 replicates) (Felsenstein, 1985).
Evolutionary distances were computed using the Maximum
Composite Likelihood method, with ambiguous positions
removed for each sequence pair (Tamura et al., 2004).
Outgroup sequences were identified through BLAST searching
for sequences of sufficient homology from other Pseudomonas
species. eBURST version 3 (eburst.mlst.net) was used to identify
clonal complexes and BURST groups (Feil et al., 2004).
Bootstrapping analysis with 2000 replicates was used for all
BURST analyses.
Minimum Inhibitory Concentration (MIC)
Assays
Resistance to commonly used antibiotics was determined using
broth microdilution minimum inhibitory concentration (MIC)
assays, as described by Wiegand et al. (2008). Antibiotics tested
were: gentamicin, ciprofloxacin, ceftazidime, piperacillin, and
amikacin, obtained from Sigma-Aldrich (Castle Hill, NSW,
Australia). Isolates were designated as being sensitive, resistant,
or having intermediate sensitivity to the antibiotics based on
Clinical and Laboratory Standards Institute (CLSI) cut-offs.
Sensitivity to CT-PA Phages and
Enumeration of Phage
The ability of the 4 phages to lyse each bacterial isolate was tested
using the spot test described by Mazzocco et al, with a drop size
of 5µL (Mazzocco et al., 2009). All plaque assays were performed
in duplicate. Enumeration of phage in stocks using the small drop
plaque assay system was performed prior to each assay, with a
concentration of 108 PFU/mL used for isolate sensitivity assays.
A selected reference bacterial strain was used for titration of each
of the 4 different phage stocks. The small drop plaque assay was
also used to assess the phage concentration in the liquid contents
of the biofilm assay wells, at 48 h after treatments were applied.
Biofilm Assay
The microtitre dish biofilm formation assay as described by
O’Toole was used to assess the ability of CT-PA to eradicate
P. aeruginosa biofilms in vitro (O’Toole, 2011). A 1.0 McFarland
unit suspension in 0.45% saline of the isolate was diluted into
10 times the volume of nutrient broth (Oxoid, Hants, UK),
and gently mixed by inversion. 150 µL/well of the resulting
suspension was plated into a clear polystyrene 96-well plate
(Greiner Bio-One, Kremsmünster, Austria). Wells adjacent to the
edge of the plate were filled with 180µL sterile PBS as a sterility
control. The plate was then incubated for 48 h on a gyratory
mixer at 37◦C. After 48 h, the liquid contents of the bacterial wells
were gently aspirated, followed by washing twice with sterile PBS
to remove any remaining planktonic cells. Treatments included
each of the 4 phages and the phage cocktail in nutrient broth
at concentrations of 107 and 108 PFU/mL, as well as equivalent
volumes of heat-inactivated stocks of the 4 phages, with PBS
as negative control and 2.5% cetylpyridinium chloride (Sigma-
Aldrich, St Louis, MO, USA) as a positive control. 180 µL of each
treatment was plated in quadruplicate and biofilms were assessed
at 24 and 48 h after treatment. Forty-eight hours treatment
plates had 50 µL/well nutrient broth replenished at 24 h. At
the designated time point (either 24 or 48 h after treatment),
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TABLE 2 | Host range of phages and phage cocktail in CRS clinical isolates.
P. aeruginosa isolate Phage treatment
Pa 193 Pa 204 Pa 222 Pa 223 CT-PA
PAO1 (reference strain) ++ ++ ++ 0 ++
Aus 1 0 0 ++ ++ ++
Aus 2 Unable to test
Aus 3 ++ ++ + ++ ++
Aus 4 ++ 0 ++ ++ ++
Aus 5 ++ ++ ++ ++ ++
Aus 6 + 0 + + +
Aus 7 + 0 ++ ++ ++
Aus 8 0 0 ++ ++ ++
Aus 9 0 0 + + +
Aus 10 ++ ++ 0 0 ++
Aus 11 0 0 0 0 0
Aus 12 ++ ++ 0 0 ++
Aus 13 0 0 0 0 0
Aus 14 ++ ++ + 0 ++
Aus 15 ++ ++ + + ++
Aus 16 ++ ++ ++ ++ ++
Aus 17 ++ ++ 0 0 ++
Aus 18 + + + + ++
Aus 19 ++ ++ + + ++
Aus 20 ++ ++ ++ ++ ++
Aus 21 0 0 0 0 0
Ned 1 + 0 0 ++ ++
Ned 2 ++ ++ ++ ++ ++
Ned 3 0 0 ++ ++ ++
Ned 4 0 0 0 0 0
Ned 5 ++ ++ ++ ++ ++
Ned 6 + ++ + + ++
Ned 7 + + ++ ++ ++
Ned 8 ++ 0 0 ++ ++
Ned 9 ++ ++ 0 0 ++
Ned 10 ++ ++ + ++ ++
Ned 11 ++ ++ ++ ++ ++
Ned 12 + 0 + 0 +
Ned 13 ++ 0 + + ++
Ned 14 0 0 + + +
Ned 15 ++ ++ ++ + ++
Ned 16 + 0 + 0 +
Ned 17 Unable to test
Ned 18 0 0 ++ + ++
Ned 19 + 0 0 0 +
USA 1-1 0 0 0 0 0
USA 1-2 0 0 + ++ ++
USA 2 ++ ++ ++ ++ ++
USA 3 ++ ++ ++ ++ ++
USA 4-2 ++ ++ ++ ++ ++
USA 5 ++ ++ + + ++
USA 6 + + ++ + ++
Total CI sensitive (%) 33 (73) 24 (53) 33 (73) 32 (71) 40 (89)
Total CI resistant (%) 12 (27) 21 (47) 12 (27) 13 (29) 5 (11)
++, Full activity spots on small drop plaque assay.
+, Partial activity spots on small drop plaque assay.
0, No activity on small drop plaque assay.
CI, clinical isolates.
The bold values are the number (count) of isolates, as opposed to the percentage of
isolates shown in parentheses.
liquid contents of the wells were transferred into a fresh plate
for post-treatment phage titration. The biofilm plates were gently
washed twice with sterile PBS, and then stained with 190 µL/well
0.5% crystal violet (Sigma, St Louis, MO, USA) for 30min. The
stained plates were rinsed by two rounds of gentle immersion into
distilled water, and left to dry overnight. The crystal violet stain
was eluted by application of 200 µL/well 30% acetic acid (Chem-
Supply, Adelaide, South Australia) and the plate was incubated
at room temperature for 30min. Absorbance at 595 nm was
measured for each well using the Fluostar Optima microplate
reader (BMG Labtech, Ortenberg, Germany), with 200 µL 30%
acetic acid in unstained wells used as blanks.
Statistics
Linear mixed effects models were applied to assess the effects
of group, time point, CF status and multidrug resistance
on absorbance (A595) data from the microtitre plate biofilm
formation assay. A595 values were log transformed prior to
analysis due to violations of the distributional assumptions of
linear regression. Pairwise, post-hoc comparisons for group were
assessed at p < 0.010 due to the large number of comparisons
made. The data were analyzed using SAS v9.4 (SAS Institute Inc.,
Cary, NC, USA).
RESULTS
Multiple MLST Sequence Types Identified
Amongst CRS Clinical Isolates
In total, 47 P. aeruginosa isolates were collected from the upper
and lower airways from 44 patients suffering from CRS and/or
CF in 3 continents. These included 19 isolates from the upper
and lower respiratory tracts of patients with CF (Amsterdam,
Netherlands), 7 sinus isolates from CRS patients with and
without CF (Birmingham, AL, USA), and 21 sinus isolates
from CRS patients with and without CF (Adelaide, Australia).
Isolate characteristics are displayed in Table 1. MLST revealed 44
distinct sequence types. Isolate MLST profiles and burst groups
are detailed in Supplementary Table 1. One clinical isolate from
a CF patient in the Netherlands was of the same sequence type
as PA01. Two Australian non-CF isolates shared an identical
sequence type (348), and another sequence type (274) was shared
TABLE 3 | Antibiotic resistance of clinical isolates.
No. of resistant isolates (%)
CF isolates Non-CF isolates All isolates
Gentamicin 9 (43) 1 (5) 10 (25)
Amikacin 10 (48) 1 (5) 11 (28)
Ciprofloxacin 13 (62) 2 (11) 15 (38)
Ceftazidime 12 (57) 1 (5) 13 (33)
Piperacillin 3 (14) 0 (0) 3 (8)
Multidrug resistant 11 (52) 0 (0) 11 (28)
Total no. of isolates tested 21 19 40
The bold values are the number (count) of isolates, as opposed to the percentage of
isolates shown in parentheses.
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FIGURE 3 | Absorbance at 595 nm of crystal violet-stained biofilms. Biomass of biofilms (of all 40 isolates and ATCC 15692) as measured by absorbance at 595 nm
of crystal violet-stained biofilms after treatment with: (A) 107 PFU/mL phage treatments or growth media control for 24 h, (B) 108 PFU/mL phage treatments or
growth media control for 24 h, (C) 107 PFU/mL phage treatments or growth media control for 48 h, (D) 108 PFU/mL phage treatments or growth media control for
48 h. Boxplot whiskers represent range (minimum to maximum values). (NB: nutrient broth; **p < 0.01; ***p < 0.001).
by one isolate from each of Australia, the United States, and the
Netherlands.
BURST analysis identified only one clonal complex, using
the most stringent definition of sequence types sharing six or
more alleles in common. The clonal complex consisted of two
single locus variants isolated from the same CF patient. The
phylogeny inferred by the Neighbor-Joining method is displayed
in Figure 1.
CT-PA Host Range in CRS Clinical Isolates
40/45 isolates (89%) were lysed by CT-PA, with partial or full
activity spots seen on the small drop plaque assay. Examples
of full and partial activity spots are shown in Figure 2. Two
isolates could not be tested; one due to interference from plaques
throughout the bacterial lawn including areas where the phage
had not been applied (thought to be due to induction of a
prophage), and the other due to poor growth in culture. When
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FIGURE 4 | Percentage reduction in biofilm biomass with CT-PA treatment.
Percentage reduction in biofilm biomass compared to growth media control
after 24 and 48 h treatment with lower and higher concentrations of CT-PA.
Dots represent the average of quadruplicate treatments, and horizontal lines
indicate median values.
tested individually, 73, 53, 73, and 71% of isolates were sensitive
to Pa 193, Pa 204, Pa 222, and Pa 223 respectively, as displayed in
Table 2. 39/45 isolates (87%) were susceptible to 2 or more of the
4 phages.
Multidrug Resistance in CF Clinical
Isolates
Isolates that displayed sensitivity to CT-PA were tested for
antibiotic resistance, using CLSI cut-offs for intermediate
resistance and resistance. The number of isolates displaying
resistance or intermediate resistance to the five antibiotics tested
is shown in Table 3. Eleven isolates, all from CF patients, were
multidrug resistant according to the definition proposed by
Magiorakos et al. (2012).
Biofilm Reduction by CT-PA
All 40 isolates that displayed sensitivity to CT-PA on the spot
test assay, as well as reference strain ATCC 15692, were tested
using the microtitre dish biofilm assay. Absorbance readings
from the crystal violet biofilm assays of all isolates at 24 and
48 h after treatment are displayed in Figure 3. Statistically
significant reductions in biofilm biomass compared to the
negative treatment control (nutrient broth) were seen with both
107 and 108 PFU/mL of CT-PA, Pa 222 and Pa 223 at both 24 and
48 h (p < 0.001). Significant reductions were also seen with 107
PFU/mL Pa 193 and 108 PFU/mL Pa 204 at 48 h (p < 0.01).
For all isolates tested, the median biofilm biomass reduction
was 70% and 64% after 48 h treatment with the lower and higher
concentrations of CT-PA, respectively. 34 (85%) and 32 (80%) of
the clinical isolates, respectively showed a reduction in biomass
compared to the negative treatment control at 48 h, as displayed
in Figure 4. The median biomass reductions at the 24-h time
point were similar for both concentrations of CT-PA at 67%. The
maximum biomass reductions were 98.6 and 99.6% at 24 h, and
99.4 and 98.8% at 48 h, for the lower and higher concentrations,
respectively.
Analysis of two-way interactions showed no statistically
significant interactions between CF status ormultidrug resistance
and treatment effect.
Post-treatment Phage Titres
For all except three of the 40 isolates tested, titres of two or
more of the four phages had increased after 48 h treatment in
the biofilm assay. This indicates successful phage infection and
replication, and good complementation between the four phages
comprising the CT-PA cocktail. Of the remaining three isolates,
two showed an increase in titres of one phage, and one did not
show an increase in any phage titres. Post-treatment phage titres
for PAO1 and the 40 clinical isolates are displayed in Table 4.
DISCUSSION
CT-PA bacteriophage cocktail displayed suitable anti-biofilm
activity in vitro. It had a broad host range in the 45 isolates tested,
with 89% of isolates susceptible. The use of a cocktail as opposed
to individual phages increased the host range significantly, with
only 53–73% of isolates being susceptible to each of the four
phages individually. This is consistent with previous observations
that the use of a cocktail of phages rather than individual phages
improves activity by expanding the host range and by preventing
the development of bacteriophage-insensitive mutant bacteria
(Chan and Abedon, 2012; Hall et al., 2012; Drilling et al., 2014b).
The lytic effect of CT-PA on planktonic bacteria translated
well to a reduction in biofilm, consistent with previous reports
showing efficacy of bacteriophage to reduce biofilm in vitro and
in vivo (Drilling et al., 2014a,b). Moreover, the increase in phage
titres following treatment for almost all isolates implies successful
phage infection, replication, and lysis of host bacteria, given the
strictly lytic nature of all phages comprising the CT-PA phage
cocktail.
Our results suggested slightly more biofilm removal by 107
PFU/mL compared to 108 PFU/mL CT-PA after 48 h treatment,
despite similar anti-biofilm activity of the two treatment
concentrations at 24 h. Studies of other P. aeruginosa phages have
demonstrated that a higher concentration of phage treatment
does not always result in greater magnitude of biofilm removal
or bacterial killing (Knezevic et al., 2011; Worley-Morse et al.,
2014). A non-linear relationship may be expected for some phage
combinations over time due to the self-replicating nature of
phage therapy (Abedon, 2011).
The isolates in our study sample consisted of 44 MLST
sequence types from both the sinuses of non-CF CRS sufferers,
and the upper and lower respiratory tracts of CF patients. BURST
and phylogenetic analysis was consistent with the predominantly
non-clonal population structure that has been described by
P. aeruginosa strain typing studies (Kiewitz and Tümmler, 2000;
Curran et al., 2004). Clonal groups (identical ST) and clonal
complexes were uncommon within our collection of isolates.
The clonal and BURST groups identified contain isolates from
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TABLE 4 | Post-treatment phage titres.
Strain Post-treatment phage titres (PFU/mL)
108 PFU/mL treatment 107 PFU/mL treatment
Pa 193 Pa 204 Pa 222 Pa 223 Pa 193 Pa 204 Pa 222 Pa 223
PAO1 2.0E+10 3.0E+09 4.0E+10 1.0E+08 1.0E+10 2.0E+09 2.0E+10 1.0E+09
Aus 1 1.1E+08 5.7E+07 4.9E+07 1.0E+02 4.3E+06 4.0E+06 1.8E+08 2.0E+02
Aus 3 1.8E+10 9.2E+09 4.3E+09 3.9E+09 9.0E+09 2.9E+09 8.5E+08 6.5E+02
Aus 4 3.0E+08 9.0E+08 3.0E+08 1.0E+07 7.0E+08 4.0E+09 5.0E+06 3.0E+05
Aus 5 8.0E+10 2.4E+09 6.4E+08 2.0E+03 5.0E+09 1.3E+10 1.3E+09 1.2E+09
Aus 6 7.0E+07 2.0E+09 3.2E+09 2.1E+05 7.8E+06 7.6E+10 8.3E+09 2.1E+06
Aus 7 2.2E+09 1.0E+08 5.0E+08 4.0E+08 9.0E+09 1.0E+07 2.0E+08 1.0E+09
Aus 8 2.0E+03 8.0E+08 2.0E+03 1.0E+07 3.0E+09 2.0E+09 1.0E+08 5.0E+05
Aus 9 2.0E+07 4.8E+03 2.4E+09 1.3E+03 4.1E+04 6.0E+02 7.8E+08 2.1E+03
Aus 10 5.0E+07 1.0E+11 9.3E+08 1.2E+06 3.0E+06 7.0E+09 2.0E+09 8.0E+05
Aus 12 2.3E+09 2.6E+10 5.1E+09 3.8E+03 7.3E+08 8.2E+10 4.5E+09 2.7E+04
Aus 14 2.7E+08 5.3E+10 9.0E+07 4.8E+06 1.7E+08 2.4E+09 2.0E+06 3.9E+05
Aus 15 1.2E+11 3.0E+10 1.2E+10 5.1E+10 2.0E+11 3.0E+11 4.0E+10 2.0E+05
Aus 16 2.0E+10 1.0E+11 3.0E+09 2.0E+08 1.0E+10 1.0E+10 2.0E+07 2.0E+07
Aus 17 1.9E+10 5.2E+11 1.9E+10 9.5E+06 5.9E+10 1.5E+11 1.5E+10 5.2E+06
Aus 18 9.0E+08 1.0E+08 2.0E+10 2.5E+08 3.0E+07 2.0E+07 7.0E+10 1.0E+08
Aus 19 5.0E+08 2.0E+03 3.0E+10 2.0E+03 2.0E+03 2.0E+03 1.0E+09 2.0E+03
Aus 20 1.0E+10 4.0E+10 9.0E+07 1.0E+10 2.0E+10 2.0E+03 1.7E+07 5.0E+05
Ned 1 4.0E+07 5.3E+06 7.0E+05 5.9E+03 2.2E+06 7.1E+06 9.5E+03 6.4E+03
Ned 2 7.2E+09 1.1E+10 5.7E+07 1.5E+08 8.0E+09 2.0E+08 2.1E+07 8.0E+07
Ned 3 8.0E+07 1.9E+07 3.6E+08 1.5E+08 9.8E+05 2.0E+06 3.5E+07 5.7E+08
Ned 5 2.5E+10 2.1E+11 4.0E+07 7.7E+07 1.8E+10 1.1E+11 4.0E+07 9.0E+05
Ned 6 8.6E+09 2.4E+10 7.1E+08 1.8E+09 5.1E+09 1.7E+10 1.2E+08 5.2E+08
Ned 7 6.8E+10 1.5E+09 7.4E+07 8.4E+07 5.5E+10 1.6E+09 1.2E+07 2.6E+08
Ned 8 4.3E+10 2.2E+12 2.2E+09 2.1E+06 7.1E+10 2.4E+05 3.7E+13 1.5E+11
Ned 9 2.2E+10 2.3E+10 1.2E+07 5.5E+10 4.4E+10 1.0E+11 2.3E+06 1.6E+04
Ned 10 1.7E+08 1.1E+10 5.5E+06 7.0E+04 7.0E+07 1.7E+10 3.1E+05 2.0E+06
Ned 11 1.9E+09 3.9E+09 1.2E+09 8.5E+08 9.0E+09 6.9E+09 1.5E+09 2.4E+07
Ned 12 2.0E+08 1.0E+08 5.0E+09 1.7E+05 2.5E+06 1.0E+08 8.0E+09 4.0E+05
Ned 13 4.0E+09 3.2E+07 4.6E+08 1.0E+03 5.4E+09 4.6E+09 6.2E+08 0.0E+00
Ned 14 1.1E+09 5.3E+09 1.5E+08 1.8E+07 1.5E+09 4.5E+09 6.9E+07 4.3E+07
Ned 15 2.4E+11 1.9E+10 5.3E+09 4.9E+06 6.3E+10 1.5E+10 7.3E+09 5.6E+06
Ned 16 2.0E+11 3.4E+08 1.7E+08 5.1E+07 6.8E+10 3.0E+08 4.8E+08 8.0E+06
Ned 18 3.2E+07 1.4E+07 3.7E+09 1.8E+06 2.3E+06 1.4E+06 5.4E+09 2.7E+06
Ned 19 4.2E+08 1.2E+09 7.0E+07 2.2E+07 2.3E+06 6.2E+09 0.0E+00 6.8E+05
USA 1-2 3.0E+07 1.3E+07 3.0E+09 1.0E+06 6.0E+05 1.0E+07 3.0E+03 2.0E+06
USA 2 1.0E+09 2.0E+10 1.0E+09 1.0E+05 2.0E+10 3.0E+10 1.0E+11 6.0E+04
USA 3 1.0E+08 1.0E+12 1.0E+10 1.0E+01 1.0E+07 2.0E+06 8.0E+09 8.0E+03
USA 4-2 1.4E+09 9.0E+09 1.6E+09 1.0E+08 1.0E+10 2.0E+10 2.0E+09 1.0E+07
USA 5 1.0E+09 9.0E+09 2.0E+10 1.0E+05 1.0E+11 1.0E+09 5.0E+10 3.0E+04
USA 6 2.6E+10 2.0E+11 1.2E+10 1.2E+06 3.8E+11 4.0E+11 8.0E+09 5.0E+08
both CF and non-CF CRS patients, suggesting that P. aeruginosa
sinus infections in both groups may initially be caused by similar
strains. This is consistent with the observation made by Cramer
et al that the dominant clones amongst CF patients are also
common in the environment and other human disease habitats
(Cramer et al., 2012).
However, frequent antibiotic resistance was displayed by
CF isolates, with 52% of the CF strains tested meeting the
criteria for multidrug-resistance. Rates of antibiotic resistance
in non-CF CRS isolates were much lower, and comparable to
those observed in similar studies of CRS patients and in data
from national antimicrobial surveillance programs (Kingdom
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 8 September 2017 | Volume 7 | Article 418
Fong et al. Anti-Biofilm Activity of P. aeruginosa Bacteriophages
et al., 2004; Sasikala and Sundararaj, 2012; Sader et al., 2014,
2017; AURA, 2016). Higher rates of antibiotic resistance in
P. aeruginosa isolates from CF patients compared to non-
CF patients have been well-documented (Doring et al., 2000;
Henwood et al., 2001). Although some of the isolates in our
study were from the lower respiratory tract of CF patients, a
high degree of similarity in the adaptive mutations and gene
expression of CF sinus and lung P. aeruginosa isolates has been
found (Ciofu et al., 2013). Furthermore, the paranasal sinuses
have been found to be a reservoir of recurrent pulmonary
infections in CF patients, with identical strains often identified
in the upper and lower respiratory tracts of patients (Roby et al.,
2008; Johansen et al., 2012; Aanaes, 2013; Aanaes et al., 2013).
Thus, the selective pressures in the upper respiratory tract of
CF patients, including antibiotics administered for management
of bacterial sinus infections, have potential implications for the
development of chronic lung infections (Hansen et al., 2012).
The progression to chronic P. aeruginosa lung infection in CF
has been shown to lead to deterioration in lung function and
decreased life expectancy (Mastella et al., 1999; Li et al., 2005).
The proportion of clinical isolates that were resistant to lysis
by the CT-PA phage cocktail was small (11%), and did not include
any multidrug resistant isolates. Importantly, the anti-biofilm
activity of CT-PA was not affected by multidrug resistance, or
whether the isolate was from a CF patient. The CF isolates
tested were largely comprised of isolates with a small colony or
mucoid phenotype. These phenotypes are associatedwith chronic
infection, and display increased tolerance to various antibiotics
(Nichols et al., 1988; Govan and Deretic, 1996; Haussler et al.,
1999; Guss et al., 2009; Hansen et al., 2012). These findings
suggest that phage therapy may have potential in treating CF
patients with chronic P. aeruginosa infection, for whom clinicians
are currently faced with a dilemma of how to treat respiratory
infections without creating further antibiotic resistance. We
have previously demonstrated the ability of high-volume nasal
irrigations to penetrate into the paranasal sinuses following
functional endoscopic sinus surgery (FESS). (Grobler et al., 2008)
The phage cocktail could be administered via nasal irrigations in
order to treat recurrent sinus infections following FESS.
In vivo animal studies have demonstrated enhanced bacterial
clearance and prolonged survival in phage-treated animals (in
Galleria mellonella, canine otitis, murine lung, corneal and
peritoneal P. aeruginosa infection models) (Heo et al., 2009;
Debarbieux et al., 2010; Hawkins et al., 2010; Alemayehu et al.,
2012; Fukuda et al., 2012; Beeton et al., 2015). A limited number
of early-stage clinical trials of phage therapy for treatment
of P. aeruginosa infections have been undertaken. A double-
blind randomized controlled trial of a topically-applied phage
cocktail for antibiotic-resistant P. aeruginosa chronic otitis
showed statistically significant improvement from baseline in
both symptom and clinical severity scores in the phage treatment
group (Wright et al., 2009). No such improvement was observed
in the placebo group. Conversely, two clinical trials of phage
cocktails targeting multiple bacterial pathogens (P. aeruginosa, S.
aureus, and E. coli) for treatment of burns and chronic leg ulcers,
respectively showed no significant differences between phage and
control therapies (Rhoads et al., 2009; Rose et al., 2014).
The aforementioned clinical trials all reported excellent safety
profiles. A study of long-term safety of a S. aureus phage
cocktail applied topically to sheep sinuses found no local or
systemic safety concerns (Drilling et al., 2017). Although not
widespread, clinical use of phage therapy has occurred through
phage therapy and research institutes, such as the Eliava Institute
in Tbilisi, Georgia, and the Institute of Immunology and
Experimental Therapy in Wroclaw, Poland (Sulakvelidze et al.,
2001; Kutateladze, 2015). An analysis of 153 patients treated
for various infections with phage therapy at the latter institute
revealed no major safety concerns (Mie˛dzybrodzki et al., 2012).
Whilst further evaluation and optimisation of phage cocktail
treatment of P. aeruginosa infections in CRS and CF are
required, the safety profile of phage therapy and its activity
against antibiotic-resistant isolates make it an attractive potential
therapeutic option. Further pre-clinical and clinical studies will
be of great benefit in determining whether phage therapy can
fulfill the potential demonstrated in this study.
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